The gate exit rule

Every buy and sell, December 2013 to July 2026 · point-in-time SEC XBRL · generated 9 September 2026

The criterion that buys a company is the criterion that sells it. A name is held only while it still clears all six quality gates, and it is dropped the quarter it stops. The book is rebuilt from scratch every quarter, so a holding persists only by re-qualifying on its own merits — not on how far it has already run.1

UNIVERSE US operating companies, financials and real estate excluded
GATES    revenue growth 20–80%, net income > 0, free cash flow > 0,
         ROIC ≥ 10%, FCF conversion ≥ 50%, net debt ≤ 3× EBITDA
BETA     trailing one-year beta ≤ 1.30, measured only on prices before formation
PICK     the 25 highest composite scores that remain
HOLD     one quarter, equal weight, then rebuild

What it produced

PeriodReturnBetaVolatilitySharpe
full 2014–2518.50%1.0520.19%0.79
2014–201913.96%1.0514.87%0.77
2020–202522.82%1.0424.18%0.84
same rules, no beta cap17.50%1.3424.68%0.61

1. The beta cap. The book also requires a constituent’s trailing one-year beta to be ≤ 1.30, measured only on prices before formation (the same rules, no beta cap row above is the book without it). That single constraint pulls portfolio beta from 1.34 to 1.05 and holds it there in both halves, and volatility falls in both while Sharpe is never worse. The return effect is not robust — +6.2pp in the first half and −5.3pp in the second, a sign flip that should be ignored — so the cap is a risk control, not a return engine. It is a footnote to the exit rule, not the point of it.

Putting a factor model into the mix

Can re-weighting the score toward what the market actually pays for beat the score itself? Tested honestly — no, and that is the useful answer.

An elastic-net characteristic model on the same survivorship-free panels — every fundamental as of each formation, set against the next quarter’s beta- and sector-neutral return — finds two factors carry the cross-section: quality and cash generation. It holds up out of sample: a weighting learned on 2014–2022 predicted 2023–2026 with an information coefficient of +0.048 (t = 3.9).

So the construction is held identical — six gates, beta ≤ 1.30, top 25, rebuilt quarterly — and only the ranking changes: from the composite score to a factor-weighted score whose weights are fit strictly on data before each quarter, never after. If the model knew something the score did not, the tilted book would pull ahead.

10030050020162017201820192020202120222023202420252026
Book · existing score Book · factor-tilted S&P 500
Out of sample, 2016–2026TotalCAGRVolatilitySharpe
Book — existing score+501%18.6%24.0%0.83
Book — factor-tilted+512%18.8%23.8%0.84
S&P 500+332%14.9%17.2%0.91

It does not. Out of sample the tilted book returns essentially what the score already does — +0.0pp a quarter, t = 0.25, ahead in just 10 of 42 quarters. The two curves sit on top of one another, and both clear the S&P by the same margin.

Why that is the right result. The composite score already blends quality and cash; the model, fit blind, rediscovers the same two factors — so it validates the construction rather than beating it. Re-weighting the book for a +0.0pp, t = 0.25 effect would be fitting noise, so the holdings are left exactly as they are. The model earns its keep as a standing check on what the market is paying for — a way to notice if that ever stops being quality and cash — not as an override.

Trading activity

Formations 51Buys 580Sells 555 Mean names held 22.3Mean holding spell 2.2 quarters

The book is rebuilt from scratch every quarter, so a name persists only by re-qualifying on its own merits. Fewer than 25 names appear whenever the beta screen leaves a thinner eligible set than the gates alone would.

Longest-heldConsecutive quarters
VRTX10
HAS7
STMP7
HCCI7
AMZN6
SWBI6
MERC6
MED6

Every buy and sell

Step through the formations. Buys are companies entering the book that quarter; sells are companies that were held and no longer qualify. The table beneath is the resulting portfolio, with the trailing beta each name was screened on. Mean name beta is the average of those trailing figures, which is not the same thing as the book’s realised beta of 1.05 — the first is measured before formation, the second from what actually happened after.

Formed 2026-07-01Priced to 2026-09-04Held 25Cleared the gates 60Mean name beta 0.74Book £864,354 → £899,141

Bought — 12

CFANIPGMEDFIVEFICOLGNDFSSHUBSPNTGISRGGWRECOCO

Sold — 12

ADUSEQTFSLRHLHRMYKEQUNXTOPXSPRGSRDVTSDWLDN
TickerCompanySectorScoreBeta GrowthMarket capReturnStatus
CFCF INDUSTRIES HOLDINGS INCMaterials79.6-0.7421%$16.5bn+23.9%new
CODACODA OCTOPUS GROUP INCTechnology73.61.2923%$0.1bn+5.6%held
ANIPANI PHARMACEUTICALS INCHealthcare70.90.4937%$2.0bn-14.2%new
NBIXNEUROCRINE BIOSCIENCES INCHealthcare70.40.7329%$16.9bn-7.2%held
PTCPTC INCTechnology69.60.5328%$13.8bn+17.7%held
GMEDGLOBUS MEDICAL INCHealthcare68.90.9223%$10.3bn+3.1%new
CHECHEMED CORPHealthcare68.00.1639%$6.4bn+8.2%held
AMCRAMCOR PLCIndustrials66.60.8265%$20.2bn+3.5%held
FIVEFIVE BELOW INCConsumer Disc65.91.2126%$10.1bn+38.1%new
PAYSPAYSIGN INCTechnology65.60.8843%$0.5bn+57.1%held
VMDVIEMED HEALTHCARE INCHealthcare65.20.5423%$0.5bn-22.7%held
RELYREMITLY GLOBAL INCTechnology64.91.2827%$4.8bn+14.0%held
GRNDGRINDR INCTechnology62.40.6331%$2.8bn-2.8%held
LMBLIMBACH HOLDINGS INCIndustrials60.81.2222%$0.9bn-35.8%held
KTBKONTOOR BRANDS INCConsumer Disc59.80.9921%$4.6bn-12.2%held
FICOFAIR ISAAC CORPTechnology56.50.7223%$28.0bn-22.7%new
NOWSERVICENOW INCTechnology56.00.7322%$109.1bn+33.5%held
LGNDLIGAND PHARMACEUTICALS INCHealthcare55.70.8951%$6.2bn-8.5%new
FSSFEDERAL SIGNAL CORPConsumer Disc55.71.0923%$7.8bn-6.4%new
HUBSHUBSPOT INCTechnology54.90.7121%$9.6bn+31.9%new
KRYSKRYSTAL BIOTECH INCHealthcare54.10.8225%$10.9bn-3.6%held
PNTGPENNANT GROUP INCHealthcare54.10.4637%$1.3bn+1.7%new
ISRGINTUITIVE SURGICAL INCHealthcare52.80.8521%$142.5bn-8.9%new
GWREGUIDEWIRE SOFTWARE INCTechnology49.40.6125%$10.6bn+27.2%new
COCOVITA COCO COMPANY INCConsumer Staples48.40.5723%$3.9bn-20.1%new

Book value against the index

Both start at £100,000 on 31 December 2013.

Gross of dealing costs, FX, spread and tax. Prices are split- and dividend-adjusted closes; the universe is survivorship-free and delisted names are liquidated at their last traded price. Every fundamental figure is stamped to the date it first became public, and each trailing beta uses only prices before its formation date. The beta screen needs a year of prior prices, so the first two formations of 2014 draw on a thinner eligible set. Fifty-one quarterly formations is a small sample and none of these figures is significance-tested.